Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.72 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951843 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12951757 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12951765 | 0.89 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL14898515 | 0.88 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12938842 | 0.87 | HDAC6 (0.77) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12938831 | 0.86 | HDAC6 (0.87) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12951839 | 0.85 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12951846 | 0.85 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| SCHEMBL12951845 | 0.84 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 | |
| Tubastatin A SCHEMBL29356061 | 0.84 | HDAC6 (1.00) | HDAC6HDAC1HDAC10HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | HDAC1, HDAC9, HDAC5 | HDAC6 7/4885HDAC1 1/4885HDAC10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.